[Combination or monotherapy of hyperlipoproteinemia typus IIb, IV, V with clofibrate and m-inositolnicotinate or clofibrinic acid (author's transl)]. 1978

W Schwartzkopff, and M Zschiedrich

Clofibrate and m-Inositolnicotinate in a daily dosage of 1,5 g Clofibrate and 1,2 g m-Inositolnicotinate during long term treatment effected a good triglyceride fall in all three lipoprotein fractions, especially in VLDL. The changing of the hyperlipoproteinemia phenotypus IV to the phenotypus IIb or IIa under monotherapy with Clofibrate or clofibrinic acid could not be avoided by the combination of Clofibrate with m-Inositolnicotinate. Approximately every fourth hyperlipoproteinemia phenotypus IV or V, treated with a combination therapy, had an increase of beta-Cholesterol in the pathological range of more than 210 mg/dl. The combination of Clofibrate with nicotinic acid is not of greater value than the monotherapy with Clofibrate (Atromid S). A combination of Clofibrate and nicotinic acid is useful when pure nicotinic acid (3 to 4g/daily) or its esters, for example m-Inositol-nicotinate (4 to 6g/daily) or beta-Pyridylcarbinol (800 to 1200 mg/daily) are administered in therapeutic doses. With the increased dosage of nicotinic acid, one must expect a large "drop out" of these appropriate hyperlipoproteinemia patients because of the side-effects resulting from this particular treatment with nicotinic acid.

UI MeSH Term Description Entries
D006949 Hyperlipidemias Conditions with excess LIPIDS in the blood. Hyperlipemia,Hyperlipidemia,Lipemia,Lipidemia,Hyperlipemias,Lipemias,Lipidemias
D007294 Inositol An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction. Myoinositol,Chiro-Inositol,Mesoinositol,Chiro Inositol
D008077 Lipoproteins, LDL A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues. Low-Density Lipoprotein,Low-Density Lipoproteins,beta-Lipoprotein,beta-Lipoproteins,LDL(1),LDL(2),LDL-1,LDL-2,LDL1,LDL2,Low-Density Lipoprotein 1,Low-Density Lipoprotein 2,LDL Lipoproteins,Lipoprotein, Low-Density,Lipoproteins, Low-Density,Low Density Lipoprotein,Low Density Lipoprotein 1,Low Density Lipoprotein 2,Low Density Lipoproteins,beta Lipoprotein,beta Lipoproteins
D008079 Lipoproteins, VLDL A class of lipoproteins of very light (0.93-1.006 g/ml) large size (30-80 nm) particles with a core composed mainly of TRIGLYCERIDES and a surface monolayer of PHOSPHOLIPIDS and CHOLESTEROL into which are imbedded the apolipoproteins B, E, and C. VLDL facilitates the transport of endogenously made triglycerides to extrahepatic tissues. As triglycerides and Apo C are removed, VLDL is converted to INTERMEDIATE-DENSITY LIPOPROTEINS, then to LOW-DENSITY LIPOPROTEINS from which cholesterol is delivered to the extrahepatic tissues. Pre-beta-Lipoprotein,Prebeta-Lipoprotein,Prebeta-Lipoproteins,Very Low Density Lipoprotein,Very-Low-Density Lipoprotein,Very-Low-Density Lipoproteins,Lipoprotein VLDL II,Lipoproteins, VLDL I,Lipoproteins, VLDL III,Lipoproteins, VLDL1,Lipoproteins, VLDL2,Lipoproteins, VLDL3,Pre-beta-Lipoproteins,Lipoprotein, Very-Low-Density,Lipoproteins, Very-Low-Density,Pre beta Lipoprotein,Pre beta Lipoproteins,Prebeta Lipoprotein,Prebeta Lipoproteins,VLDL Lipoproteins,VLDL1 Lipoproteins,VLDL2 Lipoproteins,VLDL3 Lipoproteins,Very Low Density Lipoproteins
D009539 Nicotinic Acids 2-, 3-, or 4-Pyridinecarboxylic acids. Pyridine derivatives substituted with a carboxy group at the 2-, 3-, or 4-position. The 3-carboxy derivative (NIACIN) is active as a vitamin. Acids, Nicotinic
D009540 Nicotinyl Alcohol Alcohol analog of NICOTINIC ACID which is a direct-acting peripheral vasodilator that causes flushing and may decrease blood pressure. It is used in vasospasm and threatened GANGRENE. Nicotinic Alcohol,Nicotinyltartrate,Pyridylcarbinol,3-Hydroxymethylpyridine,Nicomethanol Hydrofluoride,Pyridine-3-Methanol,Radecol,Roniacol,Ronicol,Ronicol Retard,beta-Pyridylcarbinol,3 Hydroxymethylpyridine,Alcohol, Nicotinic,Alcohol, Nicotinyl,Hydrofluoride, Nicomethanol,Pyridine 3 Methanol,beta Pyridylcarbinol
D002914 Chylomicrons A class of lipoproteins that carry dietary CHOLESTEROL and TRIGLYCERIDES from the SMALL INTESTINE to the tissues. Their density (0.93-1.006 g/ml) is the same as that of VERY-LOW-DENSITY LIPOPROTEINS. Chylomicron
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D002994 Clofibrate A fibric acid derivative used in the treatment of HYPERLIPOPROTEINEMIA TYPE III and severe HYPERTRIGLYCERIDEMIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986) Athromidin,Atromid,Atromid S,Clofibric Acid, Ethyl Ester,Ethyl Chlorophenoxyisobutyrate,Miscleron,Miskleron,Chlorophenoxyisobutyrate, Ethyl
D004083 Cholestanol A cholesterol derivative found in human feces, gallstones, eggs, and other biological matter. Coprostanol,Dihydrocholesterol,beta-Cholestanol,5 alpha-Cholestan-3 alpha-ol,5 alpha-Cholestan-3 beta-ol,5 beta-Cholestan-3 alpha-ol,5 beta-Cholestan-3 beta-ol,Cholestan-3-ol,Cholestanol, (3alpha, 5beta)-Isomer,Coprosterol,5 alpha Cholestan 3 alpha ol,5 alpha Cholestan 3 beta ol,5 beta Cholestan 3 beta ol,Cholestan 3 ol,beta Cholestanol,beta-Cholestan-3 beta-ol, 5,beta-ol, 5 beta-Cholestan-3

Related Publications

W Schwartzkopff, and M Zschiedrich
April 1978, MMW, Munchener medizinische Wochenschrift,
W Schwartzkopff, and M Zschiedrich
December 1973, Deutsche medizinische Wochenschrift (1946),
W Schwartzkopff, and M Zschiedrich
May 1977, MMW, Munchener medizinische Wochenschrift,
W Schwartzkopff, and M Zschiedrich
May 1973, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,
W Schwartzkopff, and M Zschiedrich
October 1974, Zeitschrift fur Orthopadie und ihre Grenzgebiete,
W Schwartzkopff, and M Zschiedrich
March 1974, Deutsche medizinische Wochenschrift (1946),
W Schwartzkopff, and M Zschiedrich
January 1973, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
Copied contents to your clipboard!